Growing disease burden opens wider market for Zimbabwe health products

Zimbabwe's changing disease burden is creating demand for a broader range of pharmaceutical, nutrition, wellness and health-promotion products, according to a presentation on the country's pharmaceutical ecosystem.

The presentation by Zimpharm Pvt Ltd's Norman Z. Nyazema says Zimbabwe's health landscape has undergone rapid transformation since independence in 1980, with increased life expectancy and reduced infant mortality.

It says the disease burden is increasingly being defined by disability rather than premature mortality, while identifying poor nutrition, inadequate access to clean water and sanitation, and preventable infectious diseases among factors contributing to illness.

The presentation highlights HIV, malaria, tuberculosis and cholera among the preventable infectious diseases contributing to the country's health burden. It also points to poor nutrition as a growing concern, arguing that the consumption of unhealthy food has emerged as a major risk factor for illness.

At the same time, Zimbabwe is moving closer to the historical Abuja Declaration, according to the presentation's reference to the National Health Strategy 2026-2030, which it says has a ZW$30 billion allocation.

The presentation estimates Zimbabwe's population in 2026 at approximately 17.3 million, with 40 percent living in urban areas. It says malnutrition remains a significant public health concern and continues to affect child development.

Against this background, the presentation identifies markets for products addressing communicable diseases such as malaria, tuberculosis and HIV, as well as neglected tropical diseases including schistosomiasis and helminthiasis.

It also identifies non-communicable diseases such as cardiovascular disease, cancer and diabetes, together with child immunisation and maternal and child health, as areas generating demand for health-related products and services.

The presentation cites an estimated market opportunity of between US$265 million and US$431 million over the next decade, linking the opportunity to a joint SADC call for support towards industrialisation and productive sectors.

Beyond medicines, Nyazema points to an expanding market for health-promotion products and a broader concept of healthcare in which nutrition and wellness form part of the pharmaceutical ecosystem.

"HEALTH IS NOT ONLY THE ABSENCE OF DISEASE," the presentation states, underscoring the argument that Zimbabwe's health market is extending beyond the traditional manufacture and distribution of medicines.